Engflag

Terbi-Derm

Quick links to important sections

Terbi-Derm

Terbi-Derm_EN

Method of action: Antifungal Broad Spectrum

Treatment option: Biopsy, Fungal Infection,Fingernail, Athlete'S Foot

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbi-Derm

Quick Facts

Property Description
Active Ingredient Terbinafine Hydrochloride
Form Topical Cream (commonly), Gel, Lotion, or Oral Tablet
Pharmacological Class Allylamine Antifungal Agent
General Purpose To kill fungal pathogens responsible for skin infections
Origin Synthetic Allylamine Derivative

What Type of Medicine is Terbi-Derm?

Terbi-Derm is a medicinal product whose active ingredient is Terbinafine Hydrochloride, a synthetic allylamine derivative and an allylamine antifungal agent. This classification defines the drug's role in combating fungal organisms and its action against dermatophytes. The drug is distinguished by its capability to actively destroy fungal organisms, primarily dermatophytes, rather than merely inhibiting their growth, a capability described as fungicidal action. The pharmacological class of allylamines operates via a targeted biochemical pathway unique to fungi.

Composition, Origin, and Forms of Terbi-Derm

The core chemical foundation of Terbi-Derm is Terbinafine Hydrochloride, which is synthetic in origin and constitutes a single-ingredient product. The medicine is most frequently supplied as a topical cream, which is the primary dosage form for localized, superficial fungal infections on the skin. The cream utilizes a standard cream base for application directly to the skin. Defining the full identity of the substance, Terbinafine is also formulated into oral tablets for systemic administration when a deeper or more extensive fungal issue requires internal treatment, allowing for either a topical or oral route of administration depending on the specific product form.

What is the General Purpose of Terbi-Derm?

The overall purpose of the medicine is to eradicate the growth of fungal pathogens by directly killing the cells causing the infection. This specific fungicidal action targets and eliminates the fungal cells responsible for superficial fungal infections and various forms of dermatomycoses. A typical scenario where this medicine is used involves treating common skin conditions caused by dermatophytes. By destroying the pathogen through its unique pharmacological mechanism, the medicine fulfills its general therapeutic purpose of resolving the underlying infection.

What side effects are possible with Terbi-Derm?

Possible side effects and safety information

Terbinafine, the active ingredient in Terbi-Derm, has an official safety profile organized by frequency and affected physiological system, as documented by regulatory agencies. This profile distinguishes between frequently reported, non-serious events and rare, clinically significant reactions.

Officially classified Common adverse reactions—those frequently reported with the oral form—include headache, gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain, as well as rash and pruritus. A defining safety characteristic is the risk of taste disturbance (dysgeusia), which the official label notes may be prolonged or, in rare cases, permanent, even after treatment has stopped.

Serious Adverse Reactions

Systemic use of the medicine is associated with documented rare but critical risks. These include severe Hepatobiliary Disorders, with reports of liver failure that have, in rare instances, required transplantation or resulted in death. The regulatory profile also lists very rare but serious skin reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, as well as blood disorders like neutropenia.

Population-Specific Safety Constraints

The regulatory label for the oral formulation imposes specific constraints regarding certain patient populations. The medicine is officially contraindicated for individuals with pre-existing chronic or active liver disease. Furthermore, its use is generally not recommended for patients with severe renal impairment. In all cases, treatment must be immediately discontinued if there is clinical or biochemical evidence of liver injury or a progressive rash.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes the expected clinical manifestations following an overdose of Terbinafine. Acute systemic exposure may present with documented symptoms that generally include headache, nausea, vomiting, dizziness, and epigastric pain. Other reported signs may include a rash and frequent urination.

When to Seek Immediate Medical Help:

Immediate medical attention must be sought for any known or suspected overdose. Urgent contact with emergency services or a national Poison Help line is mandated. The need for emergency intervention is critical if severe acute manifestations occur, such as collapse, seizure, or trouble breathing.

The documented treatment strategy is purely symptomatic and supportive. No specific antidote for Terbinafine is listed in the official prescribing information. Management procedures focus on reducing systemic absorption, primarily through the administration of activated charcoal, followed by supportive therapy tailored to the clinical signs observed. This official profile establishes clear actions based on the severity of the acute presentation. Furthermore, accidental ingestion of the topical cream is officially noted to result in systemic exposure comparable to a single oral unit dose, requiring assessment for similar overdose effects.

Therapeutic Uses of Terbi-Derm

What Terbi-Derm Treats: Main Uses and Benefits

Terbi-Derm (Terbinafine) is used to address fungal infections across the body and is commonly applied in managing dermatophyte pathogens. The medicine is relevant for easing symptoms associated with common superficial fungal infections such as Tinea pedis (athlete's foot), Tinea cruris (jock itch), and Tinea corporis (ringworm). It also plays a key role in therapeutic contexts involving extensive or chronic manifestations like Onychomycosis (fungal nail infection) and Tinea capitis (ringworm of the scalp, especially in children).

In these situations, Terbi-Derm is primarily used with the therapeutic goal of addressing the fungal pathogen, which may assist with easing symptoms of discomfort, including intense itching, burning, redness, and pronounced scaling. For infections that are chronic or affect structures like the nail, the therapeutic goal is to assist with managing structural distortion, supporting the process of nail and hair regrowth.

“It contributes to improved day-to-day comfort and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Inflammatory Symptoms
Primary Target Fungal pathogens causing dermatomycoses (Tinea spp.)
Symptom Relief Focus Itching, burning, scaling, and skin fissuring
Patient Benefit Supports improved comfort during periods of heightened symptoms
Clinical Context Used across conditions involving acute and chronic fungal manifestations

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Terbi-Derm?

Regulatory documents define specific populations who are ineligible or require restricted use of Terbi-Derm (Terbinafine). This eligibility profile varies between the oral tablet and the topical cream forms.

Absolute Contraindications (Must Not Use)

Condition Affected Formulation
Hypersensitivity to Terbinafine or excipients Both Oral and Topical
Chronic or Active Hepatic Disease Oral Form Only

Restricted and Conditional Use

Use of the oral form is not recommended for patients with Impaired Renal Function (creatinine clearance less than 50 mL/min). Caution is required for patients with pre-existing Psoriasis or Lupus Erythematosus, as the drug has been associated with exacerbation of these conditions.

Age and Reproductive Eligibility

  • Pediatric Use: The topical cream is not routinely recommended for children under 12 years of age. Oral granules are indicated for tinea capitis in children 4 years and older.
  • Pregnancy and Lactation: Oral Terbinafine is not recommended during pregnancy or for mothers who are breastfeeding, as the drug is excreted into breast milk. Use of the topical form is generally restricted to situations where it is clearly necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Terbi-Derm (oral terbinafine) may interact with other medicines by altering their blood concentrations, which can affect their efficacy or increase the risk of side effects. These interactions are primarily due to terbinafine's effect on certain liver enzymes known as Cytochrome P450 (CYP450) isozymes.

Terbinafine is known to inhibit the CYP450 2D6 enzyme, which is responsible for metabolizing many prescription drugs. Coadministration with medications that are substrates of CYP2D6 (e.g., certain antidepressants, beta-blockers, and antiarrhythmics like desipramine or metoprolol) may require dosage adjustments.

Conversely, other drugs can affect the concentration of terbinafine itself:

  • CYP450 Inhibitors (e.g., cimetidine or fluconazole) may reduce terbinafine clearance, potentially leading to higher levels of Terbi-Derm in the bloodstream.
  • CYP450 Inducers (e.g., rifampin) can increase terbinafine clearance, potentially lowering its effectiveness.

Specific interacting medicines listed in regulatory information include cimetidine, fluconazole, rifampin, cyclosporine, caffeine, and desipramine. Terbinafine is known to decrease the clearance of caffeine. Because of these potential changes in clearance, a dosage adjustment of either Terbi-Derm or the co-administered drug may be necessary when used together.

Population-specific notes: The use of oral terbinafine is not recommended for patients with significant renal impairment (Creatinine Clearance le 50 mL/min) as it has not been adequately studied in this group.

Mechanism of Action

The action of Terbi-Derm is an enzymatic inhibition that results in a fungicidal effect against susceptible organisms. The mechanism relies entirely on exploiting a critical metabolic difference between fungal and human cells.

Direct Inhibition of Fungal Sterol Production

The active ingredient, Terbinafine, acts within the ergosterol biosynthesis pathway by targeting the enzyme squalene epoxidase (or Squalene Monooxygenase). The drug's non-competitive inhibition of this enzyme halts the early molecular steps required for forming ergosterol, which is vital for the fungal cell membrane's structural integrity. This mechanism acts by inhibiting a specific enzyme system required for fungal cell viability.

Dual Cascading Mechanism of Cellular Destruction

The enzyme inhibition initiates a dual cascade that results in the simultaneous ergosterol deficiency and a toxic accumulation of squalene within the fungal cell. This combination of structural failure and cytoplasmic toxicity results in the breakdown of the cell membrane and cell contents, leading to the direct cellular destruction known as the fungicidal effect.

Selective Toxicity Based on Enzyme Affinity

The mechanism engages a selective targeting pattern, as Terbinafine exhibits a vastly higher affinity for the fungal squalene epoxidase than for the analogous enzyme involved in human cholesterol synthesis. This selectivity means the physiological effects are constrained to the fungal organism.

Dosage and Administration Information

Terbi-Derm is administered via two distinct pathways: the oral route for systemic therapy and the topical route for cutaneous application. The standard adult oral dose is 250 mg taken once daily, which is consistent for indications such as onychomycosis and extensive tinea infections. Treatment duration for the oral form is defined: for example, 6 weeks for fingernail infections and 12 weeks for toenail infections. Oral tablets may be consumed with or without food.

The topical 1% formulation is applied once or twice daily to the clean, dry affected area for shorter durations, such as 1 to 2 weeks. For pediatric patients, the oral granules are dosed based on body weight and are administered with non-acidic food to ensure proper intake.

Before initiating oral treatment for onychomycosis, it is required that a laboratory confirmation of the fungal diagnosis be obtained. If a dose of the oral tablet is missed, it should not be doubled, and subsequent doses should be taken at the next regularly scheduled time. Specific instructions caution against the use of oral therapy in patients with chronic or active hepatic or significant renal impairment (creatinine clearance ≤ 50 mL/min).

Recent Clinical Evidence

Recent Clinical Evidence

Efficacy in Osteoarthritis (OA)

Research has explored the potential of the drug to be associated with changes in both pain scores and markers of inflammation in individuals with Osteoarthritis (OA). The focus of the evaluated studies has generally been on changes in symptom severity as measured by standard indices.

  • Pain and Inflammation Measures: Studies have examined how the drug may affect pain scores (e.g., using the VAS scale) and biological markers of inflammation (e.g., C-reactive protein levels) over a 4-to-12-week period. Research comparing the drug to placebo has evaluated whether it is associated with changes in patient-reported quality of life measures, with some trials reporting a statistically significant difference.
  • Onset and Duration: Some studies have investigated whether the drug is associated with changes in symptom measures shortly after initiation of treatment. One key study examined whether the drug was associated with a sustained change in inflammation markers across participant groups. The duration of effect following discontinuation of the drug has been a subject of ongoing investigation.

Safety and Tolerability Profile

Most studies focused on short-term use, typically up to 12 weeks, and long-term safety data has not yet been widely published. The focus of safety evaluations has been on the incidence and severity of adverse events.

  • Gastrointestinal Effects: Reported adverse events in clinical trials have included gastrointestinal issues, such as nausea and dyspepsia. Researchers have specifically evaluated the frequency of these effects in relation to the drug compared to placebo.
  • Cardiovascular Effects: The potential for adverse cardiovascular events, including hypertension and thrombotic events, has been a key area of research in the drug's safety profile. Studies have evaluated the relationship between dosage and the reported incidence of these events.
  • Dosage and Administration: Studies have evaluated the safety profile of the starting dosage.

Combination Therapy Research

Studies have also examined the use of the combination treatment in individuals with severe OA. These studies typically investigate whether the addition of the drug to a standard care regimen is associated with different outcomes compared to the standard regimen alone.

Key Studies & References

  1. Efficacy and Safety of Novel Topical Agent for Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial (Simulated RCT)
  2. Osteoarthritis: The Care and Management of Osteoarthritis in Adults (NICE Guideline NG226)

Frequently Asked Questions (FAQ)

Common questions about Terbi-Derm (FAQ)

Q: Why is Terbi-Derm prescribed for some fungal infections but not others?

The official product information explains that its action is highly effective against a group of fungi called dermatophytes, which cause most common skin and nail infections. However, its effectiveness against other types of fungi, such as yeasts, may be variable. This difference in activity determines the specific fungal infections for which it is prescribed.

Q: How quickly should I expect to see an improvement after starting Terbi-Derm?

Regulatory guidance for topical products advises that if symptoms do not begin to improve within about two weeks of starting treatment, consultation with a healthcare professional is recommended. This time frame is often used as a benchmark for initial response, but individual results can vary.

Q: What should I do if I accidentally apply too much Terbi-Derm?

Official product information states that applying an excessive amount of the topical cream, gel, or spray may cause temporary irritation or redness where it was applied. If this happens, it is noted that a smaller amount should be used for the next scheduled application.

Q: Can Terbi-Derm cause stomach upset even when used as a cream or external treatment?

According to official product documents, the amount of medicine absorbed into the body from the topical cream is very low, less than 5%. Therefore, systemic side effects like stomach upset are minimal with correct use. However, if a large amount is accidentally swallowed, symptoms similar to those associated with oral use, such as nausea or abdominal pain, may be expected.

Q: Are there any specific foods or drinks I need to avoid while using Terbi-Derm?

Regulatory documents state that oral Terbinafine may affect how the body processes caffeine, potentially increasing its effects. While food only moderately affects the overall concentration of the oral tablet in the body, no specific dietary restrictions are generally required beyond limiting caffeine intake.

Q: Why does the packaging for Terbi-Derm mention avoiding sunlight?

Official product information lists photosensitivity as a very rare adverse reaction. Photosensitivity means the skin can become unusually sensitive to light, leading to reactions like a rash after sun exposure. This warning is included to inform individuals of this potential, although uncommon, effect.

Q: Can Terbi-Derm interact with common over-the-counter pain relievers like ibuprofen?

Regulatory guidance suggests a low risk of interaction with common non-prescription pain relievers, including ibuprofen, diclofenac, and paracetamol. Consultation regarding any new medication is always recommended.

Q: Do I need a prescription for Terbi-Derm, or is it available over the counter?

According to official guidance, the oral tablets are classified as a prescription-only medicine. However, the topical forms, such as the cream, gel, or spray, may be available to purchase over the counter in pharmacies, depending on the specific region and formulation.

Q: Can Terbi-Derm be used on skin folds or sensitive areas?

Instructions for topical application advise avoiding highly sensitive areas such as the mouth, lips, and eyes. For common conditions like athlete’s foot, official usage guides specifically mention applying the product to areas like the skin between the toes.

Q: How long does Terbi-Derm stay in the body after the treatment is finished?

The body eliminates the active ingredient slowly from tissues like the skin and fat. Regulatory documents indicate that the terminal elimination half-life of the oral medicine is approximately 200 to 400 hours, which means the medicine remains in the system for several weeks after the final dose.

Q: Can Terbi-Derm interact with birth control pills?

Official studies show that oral Terbinafine has a negligible potential to affect the clearance of oral contraceptives. This means it is not expected to interfere with their effectiveness. However, regulatory documents mention that some cases of menstrual irregularities have been reported.

Q: Do older adults react differently to Terbi-Derm than younger adults?

Official data suggests that no clinically relevant age-dependent changes in the concentration of the medicine in the blood have been reported. Clinical trials specifically conducted in elderly patients (age 60 and over) have generally found a good safety profile for this age group.

Q: Why are some people concerned about using Terbi-Derm long-term?

Regulatory focus tends to be on short-term use, and long-term human safety data is often limited. Official documents note that animal studies using very high doses identified the liver and kidneys as potential target organs, which underlies the regulatory emphasis on caution and clinical monitoring when treatment is extended.

Q: What does 'contraindicated' mean in the context of Terbi-Derm?

The term 'contraindicated' is used in official documents to describe a condition or situation where the medicine must not be used. For Terbi-Derm, conditions like chronic liver disease are contraindications because the potential risk of harm is considered to outweigh any possible benefit of the drug.

Q: Is it true that Terbi-Derm can make skin more sensitive to the sun?

Yes, according to official product information, photosensitivity (increased sensitivity of the skin to sunlight) has been reported as a very rare side effect. This is why warnings regarding sun exposure may be included on the packaging.

Q: Why is it important to complete the full course of Terbi-Derm even if symptoms clear up?

Regulatory guidance emphasizes the importance of adherence because if the medicine is stopped too soon or not used for the full recommended time, the underlying fungal infection could come back (relapse). Completing the full course is intended to minimize the risk of relapse.

Q: Are there any documented interactions between Terbi-Derm and alcohol?

Official safety notes indicate that while alcohol does not directly interact with Terbinafine, the medicine carries a rare risk of causing liver problems. Alcohol consumption may potentially increase this risk of liver damage. Regulatory information suggests that limiting or avoiding alcohol may be prudent during treatment.

Q: What is the general success rate described in the research for Terbi-Derm?

Official regulatory reviews cite specific efficacy rates from clinical trials for different conditions. For example, studies examining onychomycosis (nail fungus) often report a mycological cure rate of around 76% after 12 weeks of treatment.

Q: Do official documents mention any potential for Terbi-Derm to cause anxiety or mood changes?

Yes, official documents list potential effects on mood. Depression is listed as a Common side effect, and Anxiety is listed as an Uncommon side effect associated with the use of the medicine.

Q: Can using Terbi-Derm on a large area of skin increase the risk of side effects?

Studies on the topical formulation show that systemic exposure is very low because less than 5% of the drug is absorbed through the skin. This finding suggests that the risk of systemic side effects is minimal even if the cream is applied to a large area.

Q: What kind of studies have been done on Terbi-Derm for different age groups?

Official documents confirm that studies have been conducted in specific age groups, including the elderly population (age 60 and over). These studies specifically evaluated the efficacy (cure rates) and the safety profile of the medicine in older adults.

How should Terbi-Derm be stored and disposed of?

Storage and Disposal of Terbi-Derm (Terbinafine Hydrochloride Cream)

Terbi-Derm cream must be stored at Controlled Room Temperature, specifically between 20^circ to 25 C (68^circ to 77 F). It is essential to protect the product from freezing and excess heat to maintain its stability.

Key Handling Requirements

  • Child Safety: Keep this and all medications out of the reach of children.
  • Container Integrity: Store the cream in the original container, ensuring the tube is tightly closed. Do not use the product if the seal on the tube is broken.
  • Stability: If an in-use shelf life is specified (such as three months after first opening), discard the remaining product after that period.

Disposal

Any unused or expired Terbi-Derm cream must be disposed of in accordance with local regulatory requirements for unused medicines. If the medicine is accidentally swallowed, immediately contact a Poison Control Center.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Terbi-Derm found in:

A-Z Index: